ProQR Therapeutics NV held its annual general meeting on June 3, 2025. During the meeting, shareholders approved the adoption of the annual accounts for the financial year 2024. The release from liability for board members for 2024 was also approved. James Shannon was re-appointed as a non-executive board member, and Daniel de Boer was re-appointed as an executive board member. KPMG Accountants N.V. was appointed as the external auditor for the financial year 2026. The board was authorized to issue and acquire ordinary shares in the capital of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.